A small H2O-soluble ingredient of royal jelly lower cholesterol levels in liver cells by suppressing squalene epoxidase

• Published in: Heliyon Vol. 8; no. 12; p. e12286
• Main Authors: Wang, Chi, Jiang, Zhen-yu, Wang, Jing, Lou, Jia-xin, Nian, Yuan-yuan, Liu, Li-xia, Dang, Tong, Meng, Xian-mei
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.12.2022; Elsevier
• Subjects: Active ingredient component; Fatty liver disease; Royal jelly; RT-PCR; Suppress cholesterol; Royal jelly; Suppress cholesterol; Active ingredient component; Fatty liver disease; RT-PCR
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2022.e12286

Excessive cholesterol in the liver is harmful for our health and may cause many diseases, such as fatty liver disease. Many studies in human and animal models have reported that royal jelly (RJ) can be used to treat atherosclerosis. However, the real mechanisms behind this action is unclear. In this study, we investigated the efficacy of RJ on gene expression of squalene epoxidase (SE) a major enzyme involved in cholesterol biosynthesis in HepG2 cells. We found that the expression of SE was decreased in response to RJ treatment. We also found that the origin of the RJ affected its strength. To find out the active fraction of RJ in cholesterol suppression, we separated RJ into two parts based on the molecular weights using ultrafiltration membrane. We found that the fraction <10kDa from RJ had comparable effect on SE expression, especially its water-soluble part. Taken together, we think RJ suppresses cholesterol by decreasing SE gene expression in liver. The active fraction of RJ in this action is <10kDa in water-soluble form. Suppress cholesterol; Royal jelly; RT-PCR; Active ingredient component; Fatty liver disease.